You are about to leave
ALK Pro UK

You have selected a link that will take you to an external site. Click ‘cancel’ to return to ALK’s site or ‘continue’ to proceed.

September 2025
GB-NPR-2500036

This website is intended for UK healthcare professionals only. Adverse Event Reporting is at the bottom of the page.
Visit patient’s website
[mo_oauth_login]
Register

EURneffy® nasal adrenaline spray in clinical practice

Data and resources to support prescribing decisions

EURneffy Prescribing information and Adverse event reporting

Clinical evidence

EURneffy® has been evaluated in clinical pharmacology studies in adults and children weighing ≥30 kg.1

  • Pharmacokinetic data show systemic exposure to adrenaline following intranasal administration is within the range observed with intramuscular injection.2
  • Pharmacodynamic responses, including increases in systolic blood pressure and heart rate, are consistent with the known effects of adrenaline.2
  • EURneffy® was generally well tolerated.1

Treatment response in a clinical setting

In a phase 3 study in paediatric patients experiencing anaphylaxis in an oral food challenge, all patients (n=15) responded to a single dose of EURneffy®.3

Real-world evidence

Real-world data from a clinical use programme provide insight into how patients respond to EURneffy® during allergic reactions.

EURneffy® clinical overview

How EURneffy® works, clinical data and safety information

Download now

EURneffy® materials for you and your patients

Instruction for use (IFU)

Step-by-step guide on how to use EURneffy®

Download

How to use video

Video guide on when and how to use EURneffy®

Watch

Patient pocket card

Fold-out card with guidance to recognize symptoms of anaphylaxis and how to use EURneffy®

Download

Carry case

A compact case for EURneffy®, with a pocket for a patient’s IFU

Order your carry case

HCP Support pack

Materials to support patient education and correct use of EURneffy®

Order HCP support pack

Patient consultation guide

Supports conversations about EURneffy® with eligible patients

Download

Patient brochure

How to recognise severe allergic reactions and when to use EURneffy®

Download

Training device

A trainer with no active ingredient to practise how to use EURneffy®

Request

Prescribing information

Indication, dosing and safety details

See details

Allergy action plans

EURneffy® allergy action plan for adults and children at risk of anaphylaxis

Go to BSACI

Share relevant materials with patients via the patient portal

Go to the patient portal

Indication

EURneffy® is indicated for the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in adults and children weighing ≥30 kg.1

1. EURneffy® 2 mg nasal spray Summary of Product Characteristics. ALK-Abelló Ltd.
2. Ellis AK et al. Development of neffy®, an epinephrine nasal spray, for severe allergic reactions. Pharmaceutics. 2024;16:811.
3. Casale TB et al. Real-world data on the effectiveness of neffy in clinical practice. Ann Allergy Asthma Immunol. 2025.
4. EpiPen® Adrenaline (Epinephrine) Auto-Injector. Summary of Product Characteristics. 2025.

May 2026
GB-EURn-2600090